{"id":131776,"date":"2023-06-21T16:55:23","date_gmt":"2023-06-21T16:55:23","guid":{"rendered":"https:\/\/ccs.ca\/?post_type=news&p=131776"},"modified":"2023-07-10T16:36:39","modified_gmt":"2023-07-10T16:36:39","slug":"canadian-cardiovascular-society-receives-2m-to-expand-study-of-covid-19-mrna-vaccines","status":"publish","type":"news","link":"https:\/\/ccs.ca\/news\/canadian-cardiovascular-society-receives-2m-to-expand-study-of-covid-19-mrna-vaccines\/","title":{"rendered":"Canadian Cardiovascular Society receives $2M to expand study of COVID-19 mRNA vaccines\u00a0"},"content":{"rendered":"\n

With new funding, major pan-Canadian initiative broadens its scope<\/em> and extends follow-up of patients.<\/em><\/p>\n\n\n\n

<\/p>\n\n\n\n

OTTAWA <\/strong>\u2014The first national study of its kind to probe the impact of COVID-19 and COVID-19 mRNA vaccines on the heart has received a $2M boost from the Public Health Agency of Canada (PHAC) to expand and extend patient follow-up, and to do cardiac imaging on those affected.\u00a0<\/p>\n\n\n\n

MYCOVACC (Canadian Cardiovascular Society National Active Surveillance Study of MY<\/strong>ocarditis and\/or Pericarditis following mRNA CO<\/strong>VID-19 VACC<\/strong>ination) will receive an additional two years of funding, bringing the total investment in this important initiative to $3.6M over three years.  <\/p>\n\n\n\n

Led by cardiologist Dr. Nathaniel Hawkins of the University of British Columbia, MYCOVACC began in October 2022 in response to reports of rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining surrounding the heart muscle) following mRNA vaccines and COVID-19 infection.  <\/p>\n\n\n\n

\u201cThe pan-Canadian study, which involves the leading experts from cardiac care centres across the country, is working to determine if people who experience these rare heart conditions are at increased risk of future health problems,\u201d Dr. Hawkins explains. While most people make a full recovery after myocarditis and pericarditis, long-term outcomes warrant further investigation.  <\/p>\n\n\n\n

The MYCOVACC team will provide valuable insights for clinicians, public health agencies and decision-makers to inform future vaccine programs.  <\/p>\n\n\n\n

Adults and children who take part in the study will be assessed at intervals and then annually for up to three years by a participating specialist using a clinical protocol. They will also be asked to complete quality of life, mental health, physical activity, and health outcome questionnaires.  <\/p>\n\n\n\n

The new funding allows for: <\/p>\n\n\n\n